INTRODUCTION
Neurotrophic factors such as nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT3), and neurotrophin-4/5 (NT4/5) play an important role in the regulation of nervous system development and adult nervous system plasticity, maintenance of structural integrity, and mediation of defensive responses after CNS injuries. NGF, probably the most widely studied neurotrophic factor, has been found to support both peripheral sympathetic and sensory neurons (17, 46, 47, 65) , and to promote the survival of basal forebrain cholinergic neurons (16) , which project from the septum-diagonal band and basal nucleus to the hippocampus and cerebral cortex, respectively (25, 30) . Under physiological conditions, the highest NGF concentration is found in the hippocampus, whereas the basal forebrain contains a low level of NGF, suggesting that NGF is produced in these cholinergic target regions and then retrogradely transported to the cell bodies in the basal forebrain.
It has been previously reported that NGF is able to prevent hypoglycemic damage of cultured cortical and hippocampal neurons (8) and glutamate excitotoxicity (67, 68) . Intraventricular or intrahippocampal administration of NGF can protect rat hippocampus and cortex from ischemic damage (5, 27, 28, 69) . Alternatively, Ishimaru et al. (37) showed that NGF infused into the cerebroventricular system delayed rather than prevented neuronal death in the hippocampus after ischemia. The neuroprotective potency of NGF in vivo seems to be correlated with the available amount of NGF and the maintenance of NGF in brain tissue. Thus, it is well-established that NGF possesses a protective function in those brain regions which are particularly vulnerable to cerebral ischemia and chronic neurodegenerative disorders.
NGF can be quickly induced in brain tissue in response to seizures, hypoglycemia, or ischemia (24, 40) . Accordingly, Hellweg et al. (31) proposed a time course of NGF ex-pression in neurodegenerative diseases, such as Alzheimer's disease. They suggest that an initial reduction of NGF in the impaired NGF-sensitive neurons is followed by a temporary increase in NGF levels that attempts to limit neuronal damage. However, such endogenous defensive mechanisms might appear too late, too short, or too weak to protect neurons from eventual damage. Exogenous NGF may therefore serve as a promising candidate for the treatment of neurodegenerative disorders. The clinical utility of NGF, however, is limited by its inability to cross the blood-brain barrier because of its chemical properties. As a result, different efforts have been made to administer NGF to specific targets in the CNS, such as intraventricular and intrahippocampal infusion of NGF (18) and transplantation of engineered NGF-secreting cells to specific areas (26, 55) . Although these treatments effectively prevented neuronal degeneration (22, 30) , the disadvantage is evident because of the injury of brain tissue. Noninvasive approaches using different carriers to mediate the transfer of NGF across the blood-brain barrier have been also attempted (7, 20) . However, a large amount of coupling product is usually required, which could lead to immunological complications. It has been alternatively suggested that the enhancement of neurotrophic factor synthesis in the brain tissue by pharmacological intervention may be a worthwhile approach (41) . During the past decades, various endogenous and exogenous compounds have been found to induce NGF expression in brain tissue or in different cell cultures, suggesting that the biosynthesis of NGF can be modulated by the activation of specific receptors or by interaction with neurotransmitters and cytokines (9, 19, 43, 58, 59, 70) . Among these compounds, catecholaminergic neurotransmitters and their analogs have been especially noted (21) . It has been shown that activation of β-adrenoceptors by isoproterenol causes an increase in NGF gene expression in cultured astrocytes within hours. Similarly, either norepinephrine (NE) or epinephrine (EN), added in a concentration range of 0.05-0.2 mM to the cultured medium, resulted in a 2-to 3-fold elevation in NGF levels in L-M cells. These data indicate that the β-adrenergic system may be involved in the regulation of NGF synthesis and secretion. In our laboratory, clenbuterol, a lipophilic β 2 -adrenoceptor agonist, has been demonstrated to stimulate the synthesis of neurotrophic factors in different cell cultures and in brain tissues (11, 67, 68) . We found that clenbuterol was able to effectively increase the expression of NGF, bFGF, and TGF-β1 in different models, and we further demonstrated that the neuroprotective effect of clenbuterol was most likely mediated by the induction of neurotrophic factors, especially NGF. These findings support the hypothesis that pharmacological induction of NGF may be a suitable way to increase endogenous synthesis of NGF in brain tissue which may be beneficial in the treatment of neurodegenerative diseases. In this article, we focus on the regulation of NGF expression and neuroprotection, as well as the relationship between these two events after the stimulation of β 2 -adrenoceptors by clenbuterol. sequently act on neurons (64) . To follow this concept, the effect of clenbuterol on the induction of NGF was first examined in primary cultures of astrocytes prepared from the cerebral cortex of postnatal rats. The cultured astrocytes were treated with clenbuterol at different concentrations (10 -6 -10 -4 M) and the NGF mRNA level in the medium was measured by reverse-transcription polymerase chain reaction (RT-PCR) after different periods of incubation. Clenbuterol dose-dependently elevated the NGF mRNA content, which peaked at 3 h, tended to decline after 6 h, and returned to control levels 24 h after incubation. The upregulation of NGF mRNA by clenbuterol was confirmed by the increase in protein levels detected by NGF-ELISA. As shown in Fig. 1A , untreated astrocytes expressed detectable NGF protein in the range of 35-55 pg/mL, which was consistent with previous data (34) . Clenbuterol (1, 10, and 100 µM) significantly increased the NGF protein content in a dose-dependent manner in the culture medium after 4 h of incubation.
The expression of NGF in the brain under physiological conditions has been suggested to be of neuronal origin (15, 45) . Previous in vitro experiments in which the cultured neurons from different brain regions synthesized and secreted NGF supported this point (34, 48) . Our results also revealed a detectable NGF protein level in the medium of mixed rat hippocampal primary cultures. This level was dose-dependently elevated by clenbuterol after 4 h of incubation (Fig. 1B) . Clenbuterol at the most effective concentration (10 µM) caused about a 6-fold increase in NGF protein content (P < 0.001) in the hippocampal culture medium, which was much greater than that observed in the cultured astrocytes treated with the same concentration of clenbuterol. This result indicates that clenbuterol strongly upregulates the NGF expression in mixed hippocampal cultures. However, it has been reported that neurons in the CNS express only a few β-adrenoceptors if any at all. Based on the mixed hippocampal cultures containing both neurons and astrocytes, we propose that the hippocampal neurons possess the capacity to synthesize and secrete NGF and that this capacity could be largely strengthened through the neuronal-glial interactions, especially once the β 2 -adrenoceptors on the copresented astrocytes are activated by clenbuterol. The signal pathway for induction of NGF after β 2 -adrenoceptor stimulation has been suggested to be associated with the accumulation of intracellular cAMP and the activation of cAMP-dependent protein kinase A (14, 64) .
Permanent Focal Cerebral Ischemia
Based on the results obtained from the in vitro studies, the effect of clenbuterol on induction of NGF was then tested in vivo. The expression of NGF mRNA was first detected in nonischemic Long Evans rats at different time points after intraperitoneal injection of clenbuterol. An enhanced NGF mRNA level in the rat cortex was already detected at 3 h, and further elevated at 6 h after administration of clenbuterol, 0.1 mg/kg, as detected by RT-PCR. Clenbuterol (0.5 and 10 mg/kg) also increased the NGF mRNA level in nonischemic hippocampal tissue at 6 h and 10 h after injection. In another series of experiments, the time course of NGF mRNA expression in rat cortex was examined by RT-PCR immediately as well as at 3 h and 6 h after permanent focal cerebral ischemia induced by middle cerebral artery occlusion (MCAO). We found that the NGF mRNA level was gradually increased in the ischemic, untreated cortex at 0-6 h postischemia and that clenbuterol (0.1 mg/kg, i.p., 3 h before ischemia) further enhanced NGF mRNA expression at all the time points tested. NGF mRNA expression was detected by in situ hybridization as well. Semi-quantification revealed that clenbuterol increased the NGF mRNA levels 1.8-fold (P < 0.05) and 1.5-fold (P < 0.05) 6 h after ischemia compared with the untreated-ischemic control in the ipsilateral and contralateral cortex, respectively, confirming the results obtained by RT-PCR ( Fig. 2A) . Interestingly, in addition to enhanced NGF mRNA signals in the cortex, clenbuterol also increased NGF gene expression 3.7-fold and 2.9-fold in ipsilateral and contralateral hippocampus, respectively (Fig. 2B ), including CA1-3 subfields, hilus, and dentate gyrus, while NGF mRNA was only weakly detected in the dentate gyrus in saline-treated control rats.
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Fig. 2.
Clenbuterol enhances NGF mRNA expression after permanent focal cerebral ischemia in rat cortex (A) and hippocampus (B). The rats were treated with clenbuterol (0.1 mg/kg) at 3 h before focal cerebral ischemia.
Brains were removed at 6 h after ischemia and the slides were prepared for NGF mRNA in situ hybridization. Integrated optical density (IOD) of NGF mRNA signals were measured in the ipsilateral and contralateral cortex and hippocampus. The values are means ± S.D. from 10 rats. *P < 0.05, **P < 0.01 and ***P < 0.001, compared to controls. Based on data from ref. 13. assay (ELISA). NGF protein content in nonischemic rat cortex increased to 120% and 170% of control level at 10 h after administration of 0.1 and 10 mg/kg clenbuterol, respectively. Similarly, the increase in NGF protein expression was detected in clenbuteroltreated, nonischemic hippocampus. As described before, NGF gene was expressed only by neurons under physiological conditions (2) . However, the expression pattern of NGF could be largely changed after brain injury. Traumatic injury or ischemia of the adult mammalian brain results in a massive activation of glial cells. Activated astrocytes are capable of synthesizing and secreting NGF which could contribute to the neuronal recovery after brain injury. We found a significant increase in NGF level in cortical as well as hippocampal tissues after focal cerebral ischemia. The postischemic upregulation of NGF expression seems to be consistently correlated with the postischemic activation of glial cells (4) . In addition, increased release of excitatory amino acids in brain tissue may also promote expression of NGF, probably through an increase in transcription of immediate early genes (1, 3, 53, 54) .
It has been reported that β 2 -adrenoceptors are upregulated on astrocytes after lesion (52) . Under ischemic lesion conditions, clenbuterol may therefore potentially modulate astrocyte functions through activation of receptors. As shown by in situ hybridization detection of GFAP mRNA, clenbuterol (0.1 mg/kg) increased GFAP gene expression 1.4-2.3 fold (P < 0.01) in the rat cortex 7 h after focal cerebral ischemia. This result suggests that induction of NGF in brain tissue by clenbuterol may be associated with its effect on activation of astrocytes through the stimulation of β 2 -adrenoceptors (12).
Transient Forebrain Ischemia
Transient forebrain ischemia was induced in Wistar rats by occlusion of both common carotid arteries and reduction of blood pressure to 40 mm Hg for 10 min. The rats were pretreated with clenbuterol (0.5 mg/kg, i.p.) or saline 3 h before transient forebrain ischemia, and the hippocampal, cortical and striatal tissues were removed at 6 h and 3 d after ischemia to measure NGF protein content by ELISA. As shown in Fig. 3A , clenbuterol elevated the NGF protein by 33.1% (P < 0.05) in the hippocampus and by 44.4% (P < 0.05) in the cortex at 6 h after ischemia compared to the control group. However, no significant increase in the NGF level was found in the striatum. The NGF protein level in the hippocampus and the cortex of untreated rats at 3 d after ischemia was elevated by 27.1% and 23.4%, respectively, compared with the corresponding level in untreated rats at 6 h after global ischemia, where clenbuterol failed to further increase the NGF levels in all three regions (Fig. 3B) .
We assumed that repeated administration of clenbuterol could prolong or potentiate the upregulation of NGF up to 3 d after ischemia. However, multiple treatments with clenbuterol (0.5 mg/kg × 4) do not cause prolonged induction of NGF in either hippocampus or cortex. This might be due to a downregulation of β-adrenoceptors by the repeated treatment with clenbuterol, which could limit NGF induction (56, 57) .
Our results suggest that the enhanced NGF synthesis by clenbuterol appeared particularly during earlier periods after global ischemia. The increase in NGF expression in ischemic brain tissue may contribute to the upregulation of antiapoptotic oncoprotein Bcl-2 by clenbuterol (42, 72) because NGF has been shown to prevent caspase 3-induced Bcl-2 cleavage. Therefore, induction of NGF in the first hours after ischemia might be important to protect neurons from damage caused by ischemia.
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NEUROPROTECTIVE EFFECT OF CLENBUTEROL
It has been suggested that increased NGF synthesis in response to various kinds of brain injuries is an endogenous protective mechanism. Such endogenous defensive responses may not be enough to protect neurons from the following massive neurotoxicity. As we have mentioned before, clenbuterol can increase NGF expression in ischemic brain and may thereby protect neurons from damage.
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Clenbuterol Prevents Glutamate-Induced Excitoxicity in Rat Hippocampal Cultures
We know that excitotoxic injury plays a major role in the pathology of cerebral ischemia. Hippocampal neurons express glutamate receptors and are vulnerable to excitotoxicity. Primary cultures of hippocampal cells were, therefore, used to test whether clenbuterol can protect neurons from glutamate-induced damage. As shown in Fig. 4 , pretreatment with clenbuterol (1-100 µM, 4 h before 1 mM glutamate exposure) reduced neuronal damage significantly in a dose-dependent manner. When clenbuterol was added to the medium 4 h before until 18 h after excitotoxic injury including the period of glutamate exposure, the neurons were efficaciously protected against damage.
Clenbuterol Reduces the Infarct Size after Permanent Focal Cerebral Ischemia in Rat and Mouse
Permanent MCAO was performed in male NMRI mice and the infarct area was measured 48 h after MCAO by means of an imaging system. A single dose of clenbuterol 0.3 or 1.0 mg/kg administered to mice intraperitoneally at 5 h prior to the induction of MCAO reduced significantly the infarct area (P < 0.05 and P < 0.01, respectively) (68).
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Y. ZHU AND J. KRIEGLSTEIN Fig. 4 . Clenbuterol protects cultured hippocampal neurons from glutamate-induced excitotoxicity. Pretreatment: clenbuterol was added to the culture medium at 4 h before glutamate exposure; pre-and posttreatment: clenbuterol was present in the medium from 4 h before until 18 h after excitotoxic injury, including the period of glutamate exposure (1 h). The damaged neurons were detected by trypan blue exclusion at 18 h after glutamate exposure. The values are presented as means ± S.D. from 5-7 experiments. ### P < 0.001 compared to controls; *P < 0.05, **P < 0.01, and ***P < 0.001 compared to the glutamate-exposed, untreated cells (Scheffé's test). Based on data from ref. 68 .
In a rat model of permanent MCAO, Long Evans rats were treated with clenbuterol at 3 h before ischemia and the infarct volume was measured at 7 d after ischemia. Clenbuterol, at 0.01 and 0.1 mg/kg, dose-dependently reduced the cortical infarct volume. However, at high doses (1 and 10 mg/kg) clenbuterol no longer protected brain tissue, probably due to its hypotensive and hyperglycemic effects which could accelerate the ischemic tissue acidosis and tissue damage (66) .
Clenbuterol Inhibits Neuronal Apoptosis Induced by Transient Forebrain Ischemia
NGF has been found not only to prevent developmental apoptosis (38,60) but also to antagonize the neuronal apoptosis induced in vitro and in vivo by various stimuli (5, 28, 39, 63) . On the other hand, deprivation of NGF induces apoptosis in cultured neurons which may be caused by caspase-3 activation and cleavage of Bcl-2 (61). These data suggest that NGF is involved in the regulation of apoptosis. Consistent with this hypothesis, apoptosis in human neurodegenerative diseases is predominantly correlated with low neurotrophic support (10) . Therefore, induction of growth factors by drugs may lead to the development of a novel therapeutic strategy for treatment of cerebral disorders.
We have previously reported that neuronal apoptosis can be induced in the hippocampal CA1 subfield and the striatum after transient forebrain ischemia (71); furthermore, the capacity of clenbuterol to induce NGF expression was also demonstrated in this model, as described before. To test the hypothesis that clenbuterol can inhibit neuronal apoptosis, rats were treated with different doses of clenbuterol 3 h prior to ischemia. The histological evaluation was performed at 7 d after transient forebrain ischemia. At either 0.5 or 1.0 mg/kg clenbuterol reduced the number of damaged neurons in CA1 subfield by 23% (P < 0.01) and 15% (P < 0.05), respectively. The immediate injection of 0.5 mg/kg clenbuterol after ischemia (posttreatment) showed a similar neuroprotective effect (P < 0.05).
Apoptosis is characterized by morphological changes of dying cells including cell shrinkage, nuclear and plasma membrane blebbing, chromatin condensation, and the formation of apoptotic bodies. In addition, the DNA laddering is considered to be the biochemical hallmark of apoptosis (32, 51) . To evaluate whether clenbuterol is able to prevent DNA degradation induced by ischemia, gel electrophoresis and TUNEL staining were used to measure DNA laddering and to detect DNA fragmentation in situ, respectively, at 3 d after transient forebrain ischemia.
As shown in Fig. 5 , the typical DNA fragments of approximately 180 bp and its multiples were observed in the control group (lanes 3, 5, and 7). In the hippocampus, the DNA fragmentation was nearly abolished after treatment with clenbuterol 0.5 mg/kg (lane 4). Clenbuterol partially blocked the DNA fragmentation in occipital cortex and striatum (lanes 2 and 6). The results from TUNEL staining confirmed this finding. These results prove that clenbuterol can effectively antagonize apoptosis in rats induced by transient forebrain ischemia.
STIMULATION OF b 2 -ADRENOCEPTORS MEDIATES THE EFFECTS OF CLENBUTEROL ON NGF INDUCTION AND NEUROPROTECTION
Primary Cultures of Rat Astrocytes and Neurons
It has been clearly shown that the β 2 -adrenoceptor agonist clenbuterol protects neurons against damage induced by glutamate and cerebral ischemia. We attempted to clarify further whether the capacity of clenbuterol to induce NGF and to protect neurons is specifically mediated by β 2 -adrenoceptors. We have shown that primary cultures of rat cortical astrocytes exposed to clenbuterol increased dose-dependently NGF mRNA detected by RT-PCR after 3-6 h of incubation. Interestingly, this upregulation of NGF induced by clenbuterol was completely blocked by coincubation with propranolol, a β-adrenoceptor antagonist, suggesting that the activation of β-adrenoceptors caused the upregulation of the NGF synthesis in astrocytes (67) . Accordingly, the protective effect of clenbuterol against glutamate excitotoxicity in the mixed hippocampal cultures was reversed by propranolol. Propranolol alone did not influence NGF gene expression or alter the neuronal viability.
To identify the specific subtype of receptor which was responsible for the neuroprotective effect of clenbuterol, a selective β 2 -adrenoceptor antagonist butoxamine (10 µM) or a selective β 1 -adrenoceptor antagonist metoprolol (10 µM) was added together with clenbuterol (1 µM) to the rat primary cultured hippocampal cells. Butoxamine abolished the CNS Drug Reviews, Vol. 5, No. 4, 1999 
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Y. ZHU AND J. KRIEGLSTEIN Fig. 5 . Clenbuterol attenuates DNA laddering in the hippocampus (H), striatum (S) and cortex (C) detected by gel electrophoresis after 10 min of forebrain ischemia. Clenbuterol (0.5 mg/kg) was administered (i.p.) at 3 h before ischemia. Rat brains were removed at 3 d after ischemia and DNA was extracted from hippocampus, striatum and cortex, respectively. Animals in the control group received saline. Lane 7: digoxigenin-labelled marker; lanes 2, 4, and 6: clenbuterol-treated ischemic animals; lanes 1, 3 and 5: untreated ischemic animals (n = 3 for each group). Based on data from ref. 71. neuroprotection of clenbuterol, while metoprolol did not, indicating that the effect of clenbuterol against neurotoxicity was mediated selectively by activation of β 2 -receptors (unpublished results).
Permanent Focal Cerebral Ischemia
The specific type of receptor that mediates the neuroprotection of clenbuterol was further studied in vivo. The β-adrenoceptor antagonists, propranolol, butoxamine, and metoprolol were lipophilic enough to penetrate into the brain and to interact with the β 2 -adrenoceptor agonist clenbuterol. In this experiment, clenbuterol (0.3 mg/kg) was intraperitoneally administered to the mouse 5 h before MCAO, and the β-adrenoceptor antagonists were administered to mice (i.p.) 20 min before injection of clenbuterol. The infarct area was measured at 2 d after MCAO. As shown in Fig. 6A and 6B, propranolol and butoxamine abolished the neuroprotective effect of clenbuterol, whereas metoprolol did not (Fig. 6C) . In parallel experiments, none of these antagonists alone affected the infarct area compared with saline-treated controls (unpublished results). These in vivo data are consistent with the results obtained from cell culture experiments and potentially indicate that the neuroprotection by clenbuterol is mediated through the activation of β 2 -adrenoceptors.
INDUCTION OF NGF MEDIATES THE NEUROPROTECTIVE EFFECT OF CLENBUTEROL
As described above, clenbuterol is able to upregulate NGF synthesis in different culture systems and in different cerebral ischemic models; furthermore, its neuroprotective effect can be demonstrated both in vitro and in vivo. It would, therefore, be interesting to know whether the clenbuterol-induced neuroprotection is mediated by the induction of NGF.
The results from primary hippocampal cultures showed that the neuroprotective activity of clenbuterol was completely blocked by coadministration of anti-NGF-β antibodies when clenbuterol (10 µM) and NGF-antibodies (0.5 µg/mL) were present in the culture medium at 4 h before and during glutamate exposure (Fig. 7) . When the same amount of anti-NGF-β antibodies alone was added to the medium immediately after excitotoxic damage, it failed to influence the neuroprotective effect of clenbuterol. In control experiments, anti-NGF-β antibody alone had no effect on the viability of glutamatetreated and untreated cells. These data clearly indicate that pharmacologically induced NGF can cause neuroprotection.
To further support this finding, NGF antisense oligonucleotides (ODN) were used to selectively suppress the synthesis of NGF in mixed hippocampal cultures and cultured cortical astrocytes. The mixed hippocampal cultures or cultured astrocytes were treated for 30 h with 1 µM NGF antisense ODN, directed against the binding site between the intron and exon III of NGF pre-mRNA. In both culture systems NGF antisense significantly inhibited NGF protein synthesis. The NGF protein content was reduced to 50% (P < 0.05) in antisense-treated hippocampal cultures compared with control sister cultures treated with saline or random ODN. Accordingly, the neuroprotective effect of clenbuterol against glutamate-induced excitotoxicity in mixed hippocampal cultures was also clearly CNS Drug Reviews, Vol. 5, No. 4, 1999 attenuated by NGF antisense ODN (P < 0.01), while the neuronal viability was not affected by either NGF antisense alone or random ODN, indicating no unspecific toxicity for them in the culture system (Fig. 8) . This result demonstrates again that NGF is responsible for the neuroprotection caused by clenbuterol. Similar experiments performed in vivo supported this suggestion. The NGF antisense ODN was repeatedly injected into rat cortex every 12 h for 2 d before MCAO to suppress the NGF synthesis in brain tissue, and the rats received clenbuterol (0.1 mg/kg, i.p.) at 3 h prior to MCAO. The infarct volume measured at 7 d post-ischemia was reduced to about 37% in clenbuterol-treated rats compared with the control (P < 0.05). This reduction of the infarct volume was completely reversed by pretreatment with NGF antisense ODN, whereas NGF antisense ODN alone did not influence the infarct size compared with vehicle-treated rats. These data obtained from in vitro and in vivo experiments convincingly prove that induction of NGF mediates the neuroprotective effect of clenbuterol (11, 13) .
THE LOW-AFFINITY NGF RECEPTOR P75 IS INVOLVED IN THE NEUROPROTECTIVE EFFECT OF NGF
We demonstrated that clenbuterol at 1 to 100 µM concentration-dependently protected cultured hippocampal neurons from glutamate-induced excitotoxicity and that the neuroprotective effect of clenbuterol at 100 µM was similar to that of exogenous NGF at CNS Drug Reviews, Vol. 5, No. 4, 1999 CLENBUTEROL 359 Fig. 7 . Monoclonal anti-NGF antibodies abolished the neuroprotective effect of clenbuterol. The primary hippocampal cells were cultured for 14 d, then exposed to glutamate (1 mM) for 1 h. Clenbuterol (10 µM) and anti-NGF antibodies (0.5 µg/mL) were added to the culture medium 4 h before and during glutamate exposure. Neuronal damage was detected by trypan blue exclusion at 18 h after glutamate-induced excitotoxic injury. The values are means ± S.D. from 5 experiments. ### P < 0.001 compared to control; ***P < 0.001 compared to glutamate-exposed cells (Scheffé's test). Based on data from ref. 68 . genous NGF provided an effective way to support neuronal survival after neuronal injury. It is assumed that either endogenous or exogenous NGF has to bind to specific receptors, thereby producing the biological effects. The high-affinity tyrosine kinase receptor A (trkA) has been suggested to be necessary and sufficient to mediate NGF responses (23, 49, 50) . However, Ip et al. (36) showed that hippocampal neurons did not express trkA. Alternatively, the low-affinity neurotrophin receptor (p75 NTR ) is expressed in hippocampal neurons (29, 44) . It recently has been suggested that p75 NTR also functions independently from trkA through the sphingomyelin pathway and activation of transcription factor NF-kB to support neuronal survival (6, 62) . We attempted to determine whether p75 NTR mediated the neuroprotective activity of NGF in cultured hippocampal cells. The exogenous NGF (1 ng/mL) significantly protected the neuronal loss caused by glutamate in the mixed hippocampal cultures (P < 0.05), and this protection was completely blocked by coadministration of anti-p75 antibodies (10 ng/mL) (Fig. 9) . We can, therefore, conclude that in cultured hippocampal cells, p75 NTR participates in the neuroprotective mechanism of NGF. However, the mixed hippocampal cultures used in this study contain both neurons and astrocytes, and the latter expresses both p75 NTR and trkA (35) . Thus, the role of trkA and p75 NTR in protecting neurons against damage has to be further studied.
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CONCLUSIONS
The lipophilic β 2 -adrenoceptor agonist clenbuterol is capable of protecting neurons from damage. There is significant evidence that the neuroprotective potency of clenbuterol is mediated by NGF induction via stimulation of β 2 -adrenoceptors. Neuroprotection caused by pharmacologically induced synthesis of NGF may become an interesting therapeutic strategy for neurodegenerative diseases and stroke. 
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